A selective peroxisome proliferator-activated receptor γ modulator with distinct fat cell regulation properties

Journal of Pharmacology and Experimental Therapeutics

Volumn 318, Issue 2, 2006, Pages 863-871

  Fujimura, Takao ^a   Kimura, Chiaki ^a   Oe, Tomoya ^a   Takata, Yoko ^a   Sakuma, Hiroyuki ^a   Aramori, Ichiro ^a   Mutoh, Seitaro ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

[3 (2,4 DICHLOROBENZYL) 2 METHYL N(PENTYLSULFONYL) 3 HBENZIMIDAZOLE 5 CARBOXAMIDE]; AMIDE; BINDING PROTEIN; CYCLIC AMP; FK614; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PHOSPHODIESTERASE III; PIOGLITAZONE; ROSIGLITAZONE; SELECTIVE PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA MODULATOR; STEROID RECEPTOR COACTIVATOR 1; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADIPOCYTE; ADIPOGENESIS; ANIMAL CELL; ARTICLE; CELL DIFFERENTIATION; CELL FUNCTION; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; GENE EXPRESSION; INSULIN RESISTANCE; LONG TERM CARE; NONHUMAN; NUCLEOTIDE SEQUENCE; OBESITY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; TWO HYBRID SYSTEM;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; 3T3 CELLS; ADIPOCYTES; ANIMALS; BENZIMIDAZOLES; CELL DIFFERENTIATION; CERCOPITHECUS AETHIOPS; COLLAGEN; GELS; GENE EXPRESSION; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; MICE; OBESITY; PLASMIDS; PPAR GAMMA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; THIAZOLIDINEDIONES; TRIGLYCERIDES;

EID: 33745957180     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.106.102459     Document Type: Article

References (40)

1. Berger JP, Petro AE, Macnaul KL, Kelly LJ, Zhang BB, Richards K, Elbrecht A, Johnson BA, Zhou G, Doebber TW, et al. (2003) Distinct properties and advantages of a novel peroxisome proliferator-activated protein gamma selective modulator. Mol Endocrinol 17:662-676.
2. Carey GB (1998) Mechanisms regulating adipocyte lipolysis. Adv Exp Med Biol 441:157-170.
3. Deeb SS, Fajas L, Nemoto M, Pihlajamaki J, Mykkanen L, Kuusisto J, Laakso M, Fujimoto W, and Auwerx J (1998) A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet 20:284-287.
4. Degerman E, Belfrage P, and Manganiello VC (1997) Structure, localization and regulation of cGMP-inhibited phosphodiesterase (PDE3). J Biol Chem 272:6823-6826.
5. Engfeldt P, Arner P, Bolinder J, and Ostman J (1982) Phosphodiesterase activity in human subcutaneous adipose tissue in insulin- and noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 55:983-988.
6. Fujimura T, Sakuma H, Konishi S, Oe T, Hosogai N, Kimura C, Aramori I, and Mutoh S (2005) FK614, a novel peroxisome proliferator-activated receptor gamma modulator, induces differential transactivation through a unique ligand-specific interaction with transcriptional coactivators. J Pharmacol Sci 99:342-352.
7. Fujimura T, Sakuma H, Ohkubo-Suzuki A, Aramori I, and Mutoh S (2006) Unique properties of coactivator recruitment caused by differential binding of FK614, an anti-diabetic agent, to peroxisome proliferator-activated receptor gamma. Biol Pharm Bull 29:423-429.
8. Ge K, Guermah M, Yuan CX, Ito M, Wallberg AE, Spiegelman BM, and Roeder RG (2002) Transcription coactivator TRAP220 is required for PPAR gamma 2-stimulated adipogenesis. Nature (Lond) 417:563-567.
9. Gregoire FM, Smas CM, and Sul HS (1998) Understanding adipocyte differentiation. Physiol Rev 78:783-809.
10. Hallakou S, Doare L, Foufelle F, Kergoat M, Guerre-Millo M, Berthault MF, Dugail I, Morin J, Auwerx J, and Ferre P (1997) Pioglitazone induces in vivo adipocyte differentiation in the obese Zucker fa/fa rat. Diabetes 46:1393-1399.
11. Heery DM, Kalkhoven E, Hoare S, and Parker MG (1997) A signature motif in transcriptional co-activators mediates binding to nuclear receptors. Nature (Lond) 387:733-736.
12. Hotamisligil GS, Johnson RS, Distel RJ, Ellis R, Papaioannou VE, and Spiegelman BM (1996) Uncoupling of obesity from insulin resistance through a targeted mutation in aP2, the adipocyte fatty acid binding protein. Science (Wash DC) 274:1377-1379.
13. Iwaki M, Matsuda M, Maeda N, Funahashi T, Matsuzawa Y, Makishima M, and Shimomura I (2003) Induction of adiponectin, a fat-derived antidiabetic and antiatherogenic factor, by nuclear receptors. Diabetes 52:1655-1663.
14. Kletzien RF, Clarke SD, and Ulrich RG (1992) Enhancement of adipocyte differentiation by an insulin-sensitizing agent. Mol Pharmacol 41:393-398.
15. Ko L, Cardona GR, and Chin WW (2000) Thyroid hormone receptor-binding protein, an LXXLL motif-containing protein, functions as a general coactivator. Proc Natl Acad Sci USA 97:6212-6217.
16. Kubota N, Terauchi Y, Miki H, Tamemoto H, Yamauchi T, Komeda K, Satoh S, Nakano R, Ishii C, Sugiyama T, et al. (1999) PPAR gamma mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance. Mol Cell 4:597-609.
17. Lee SK, Anzick SL, Choi JE, Bubendorf L, Guan XY, Jung YK, Kallioniemi OP, Kononen J, Trent JM, Azorsa D, et al. (1999) A nuclear factor, ASC-2, as a cancer-amplified transcriptional coactivator essential for ligand-dependent transactivation by nuclear receptors in vivo. J Biol Chem 274:34283-34293.
18. Miles PD, Barak Y, He W, Evans RM, and Olefsky JM (2000) Improved insulin-sensitivity in mice heterozygous for PPAR-gamma deficiency. J Clin Invest 105:287-292.
19. Minoura H, Takeshita S, Ita M, Hirosumi J, Mabuchi M, Kawamura I, Nakajima S, Nakayama O, Kayakiri H, Oku T, et al. (2004) Pharmacological characteristics of a novel nonthiazolidinedione insulin sensitizer, FK614. Eur J Pharmacol 494:273-281.
20. Nagaoka T, Shirakawa T, Balon TW, Russell JC, and Fujita-Yamaguchi Y (1998) Cyclic nucleotide phosphodiesterase 3 expression in vivo: evidence for tissue-specific expression of phosphodiesterase 3A or 3B mRNA and activity in the aorta and adipose tissue of atherosclerosis-prone insulin-resistant rats. Diabetes 47:1135-1144.
21. Olefsky JM (2000) Treatment of insulin resistance with peroxisome proliferator-activated receptor gamma agonists. J Clin Investig 106:467-472.
22. O'Moore-Sullivan TM and Prins JB (2002) Thiazolidinediones and type 2 diabetes: new drugs for an old disease. Med J Aust 176:381-386.
23. Qi C, Surapureddi S, Zhu YJ, Yu S, Kashireddy P, Rao MS, and Reddy JK (2003) Transcriptional coactivator PRIP, the peroxisome proliferator-activated receptor γ (PPARγ)-interacting protein, is required for PPARγ-mediated adipogenesis. J Biol Chem 278:25281-25284.
24. Rachez C, Lemon BD, Suldan Z, Bromleigh V, Gamble M, Naar AM, Erdjument-Bromage H, Tempst P, and Freedman LP (1999) Ligand-dependent transcription activation by nuclear receptors requires the DRIP complex. Nature (Lond) 398:824-828.
25. Rahn Landström T, Mei J, Karlsson M, Manganiello V, and Degerman E (2000) Down-regulation of cyclic-nucleotide phosphodiesterase 3B in 3T3-L1 adipocytes induced by tumour necrosis factor alpha and cAMP. Biochem J 346:337-343.
26. Rocchi S, Picard F, Vamecq J, Gelman L, Potier N, Zeyer D, Dubuquoy L, Bac P, Champy MF, Plunket KD, et al. (2001) A unique PPARgamma ligand with potent insulin-sensitizing yet weak adipogenic activity. Mol Cell 8:737-747.
27. Ruan H and Lodish HF (2003) Insulin resistance in adipose tissue: direct and indirect effects of tumor necrosis factor-alpha. Cytokine Growth Factor Rev 14:447-455.
28. Schoonjans K, Peinado-Onsurbe J, Lefebvre AM, Heyman RA, Briggs M, Deeb S, Staels B, and Auwerx J (1996) PPARalpha and PPARgamma activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene. EMBO (Eur Mol Biol Organ) J 15:5336-5348.
29. Smith U, Axelsen M, Carvalho E, Eliasson B, Jansson PA, and Wesslau C (1999) Insulin signaling and action in fat cells: associations with insulin resistance and type 2 diabetes. Ann NY Acad Sci 892:119-126.
30. Spiegelman BM (1997) Peroxisome proliferator-activated receptor gamma: a key regulator of adipogenesis and systemic insulin sensitivity. Eur J Med Res 2:457-464.
31. Spiegelman BM and Heinrich R (2004) Biological control through regulated transcriptional coactivators. Cell 119:157-167.
32. Szalkowski D, White-Carrington S, Berger J, and Zhang B (1995) Antidiabetic thiazolidinediones block the inhibitory effect of tumor necrosis factor-alpha on differentiation, insulin-stimulated glucose uptake and gene expression in 3T3-L1 cells. Endocrinology 136:1474-1481.
33. Tang Y, Osawa H, Onuma H, Nishimiya T, Ochi M, and Makino H (1999) Improvement in insulin resistance and the restoration of reduced phosphodiesterase 3B gene expression by pioglitazone in adipose tissue of obese diabetic KKAy mice. Diabetes 48:1830-1835.
34. Tontonoz P, Hu E, Graves RA, Budavari AI, and Spiegelman BM (1994) mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer. Genes Dev 8:1224-1234.
35. Tsao TS, Lodish HF, and Fruebis J (2002) ACRP30, a new hormone controlling fat and glucose metabolism. Eur J Pharmacol 440:213-221.
36. Yamauchi T, Waki H, Kamon J, Murakami K, Motojima K, Komeda K, Miki H, Kubota N, Terauchi Y, Tsuchida A, et al. (2001) Inhibition of RXR and PPAR-gamma ameliorates diet-induced obesity and type 2 diabetes. J Clin Investig 108:1001-1013.
37. Zhao AZ, Zhao H, Teague J, Fujimoto W, and Beavo JA (1997) Attenuation of insulin secretion by insulin-like growth factor 1 is mediated through activation of phosphodiesterase 3B. Proc Natl Acad Sci USA 94:3223-3228.
38. Zhu Y, Kan L, Qi C, Kanwar YS, Yeldandi AV, Rao MS, and Reddy JK (2000) Isolation and characterization of peroxisome proliferator-activated receptor (PPAR) interacting protein (PRIP) as a coactivator for PPAR. J Biol Chem 275:13510-13516.
39. Zhu Y, Qi C, Jain S, Le Beau MM, Espinosa R 3rd, Atkins GB, Lazar MA, Yeldandi AV, Rao MS, and Reddy JK (1999) Amplification and overexpression of peroxisome proliferator-activated receptor binding protein (PBP/PPARBP) gene in breast cancer. Proc Natl Acad Sci USA 96:10848-10853.
40. Zhu Y, Qi C, Jain S, Rao MS, and Reddy JK (1997) Isolation and characterization of PBP, a protein that interacts with peroxisome proliferator-activated receptor. J Biol Chem 272:25500-25506.